2 biotech picks that could provide big returns for growth investors

Nasdaq CEO says we are entering "the golden age" of biotechnology and these ASX shares could be part of that revolution.

| More on:
a woman

You鈥檙e reading a free article with opinions that may differ from The Motley Fool鈥檚 Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

While the excitement around the biotechnology industry is not new, it's certainly increasing.

Scientists and investors alike have made noteworthy comments on this industry that you and I cannot ignore. The Nasdaq CEO, for example, is on record as saying we are entering "the golden age" of biotechnology.

Even politicians are beginning to take notice.

The Australian Health Minister Greg Hunt was quoted in the Australian Financial Review聽today noting that large US pharmaceuticals companies such as Johnson & Johnson, Pfizer, Merck, AbbVie and Eli Lilly want to invest more in Australian biotech companies.

Mr Hunt said that we are likely to see "significant investment in Australian biotech firms. They are looking at Australia as the next destination in the developed world, the emerging first-world opportunity".

That wave of investment has already begun.

In February this year, shares in聽biotechnology company聽Viralytics Ltd.聽(ASX: VLA) soared 176% in just one day after聽major U.S. pharmaceutical company聽Merck & Company announced an agreement to buy it.

So which medtech and biotech companies have the potential to provide market beating returns?

What are some exciting companies that could follow the footsteps of聽CSL Limited (ASX: CSL) or聽Cochlear Limited (ASX: COH) ?

Watch List

Here are two shares I'm keeping an eye out on:

  1. Bionomics Ltd聽(ASX: BNO) which is developing聽treatments for cancer and central nervous system disorders such as anxiety, depression and Alzheimer's disease.
  1. CogState Limited (ASX: CGS) which is聽dedicated to measuring cognition to guide decision-making in clinical trials, research, healthcare and brain injury.

They both have healthy balance sheets with enough cash to cover short term liabilities which can be an 'insurance policy' – particularly with riskier biotech companies.


Of course, its not all upside and no risk, particularly with biotech companies. Failed trials or delays in getting drug approvals can set back the company's share price significantly.

That's why having a diversified portfolio and staying focused on the company's performance is really important.

In addition to biotech, this important industry could blow up into a trillion dollar market.

Motley Fool contributor Kevin Gandiya has no position in any of the stocks mentioned. You can follow Kevin on Twitter @KevinGandiya. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on 鈴革笍 Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
鈴革笍 Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
鈴革笍 Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more

asx investor daydreaming about US shares
鈴革笍 How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more

鈴革笍 Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more